SimplaceX — Serum-Free Medium for HEK293T
Ready-to-use serum-free medium for HEK293T adherent culture — optimised for AAV production, lentiviral vector manufacturing and recombinant protein expression. No animal serum. No lot-to-lot FBS variability.
What is SimplaceX?
SimplaceX is a serum-free, protein-supplemented cell culture medium formulated for HEK293T adherent culture. It replaces FBS as the sole supplement — providing the growth factors, carrier proteins and lipids required for HEK293T proliferation and transfection efficiency, without animal serum and without the lot-to-lot variability that FBS introduces into AAV and lentiviral vector production.
SimplaceX is designed as the first medium for HEK293T serum-free adaptation — the protein supplement package supports cell attachment and growth during the transition from FBS-containing medium, making it significantly easier to adapt HEK293T cells compared to fully chemically defined media. Once cells are fully adapted to SimplaceX, transition to SimplaceCDX (fully chemically defined) is straightforward if required for GMP or regulatory reasons.
Key Features
No FBS — no lot qualification
Eliminate the FBS lot testing burden from your AAV production process. SimplaceX has a defined protein supplement package — no lot-to-lot variability in growth factor composition.
Transfection-compatible
Optimised for PEI-mediated triple transfection — the standard for HEK293T AAV production. Compatible with linear PEI 25 kDa, PEI-Max, and Ca-phosphate.
Suspension cell rescue protocol
HEK293T cells that detach during serum-free adaptation should be rescued, not discarded. SimplaceX is specifically formulated to support these cells when returned to the adherent culture.
Produktinformationen
| Parameter | Spezifikation |
|---|---|
| Format | Serum-free, protein-supplemented — ready-to-use liquid |
| Cell type | HEK293T (adherent) — also suitable for HEK293, HEK293FT |
| Hauptanwendung | AAV production, lentiviral vector manufacturing, recombinant protein expression |
| Volumes available | 500 mL, 2,000 mL — larger volumes on request |
| Frei von tierischen Bestandteilen | No animal serum — protein supplement from defined sources |
| Transfektionsverträglichkeit | PEI (linear 25 kDa), PEI-Max, Ca-phosphate, Lipofectamine |
| pH | 7.2–7.4 |
| Osmolalität | 290–320 mOsm/kg |
| Sterilität | 0.2 µm sterile filtered — sterility tested per lot |
| Lagerung | 2–8°C, protected from light — stable 12 months from manufacture |
| Dokumentation | Certificate of Analysis, data sheet — full regulatory documentation on request |
| GMP-Signalweg | In development — contact us for timeline |
SimplaceX vs. FBS-Containing Medium
| Parameter | SimplaceX | DMEM + 10% FBS |
|---|---|---|
| Chargen-zu-Chargen-Schwankungen | ✅ Defined composition — no lot qualification needed | ⚠️ FBS lot-dependent — qualification required per lot |
| Endotoxin | ✅ <1 EU/mL — controlled | ⚠️ Variable — up to 10 EU/mL in standard FBS |
| TSE/BSE-Dokumentation | ✅ Not required | ⚠️ Required — country-of-origin certification per lot |
| Nachgeschaltete Reinigung | ✅ No bovine serum proteins to remove | ⚠️ Bovine albumin co-purifies with AAV |
| GMP-Signalweg | ✅ Simpler — animal-free raw material | ⚠️ Complex — FBS highest-risk raw material category |
| Adaptation required | ⚠️ 5–10 passages for full adaptation | ✅ None |
| AAV titre (optimised) | ✅ Equivalent to FBS after full adaptation | ✅ Reference |
HEK293T Adaptation Protocol — SimplaceX
HEK293T cells adapt to SimplaceX in 5–10 passages using a stepwise FBS reduction. The most important principle: never discard suspension cells during adaptation — centrifuge them and return them to the flask.
Passages 1–3 — Gradual FBS reduction
P1: DMEM + 1% FBS + 1× SimplaceX | P2–3: DMEM + 0.5% FBS + 1× SimplaceX
Low FBS slows the transition deliberately — more stable adaptation, less cell stress.
Passages 4–6 — Fully serum-free SimplaceX
DMEM + 1× SimplaceX. At every medium change: collect medium → centrifuge 300 × g, 5 min → resuspend pellet in fresh SimplaceX → return to flask with trypsinised adherent cells.
Detachment — serum-free protocol
Preferred: PBS + 5 mM EDTA — 3–5 min at 37°C. No enzyme inactivation needed.
Alternative: 0.05% Trypsin-EDTA — centrifuge immediately to pellet, remove all trypsin, resuspend in SimplaceX.
Passages 7–25 — Growth rate recovery
Doubling time recovers over 5–20 passages. Expect 28–42h during early serum-free phase, recovering to 18–24h (FBS equivalent) by passage 15–25. Continue suspension rescue protocol throughout.
Anwendungen
AAV-Produktion
Triple transient transfection in HEK293T adherent culture — AAV2, AAV5, AAV8, AAV9 and novel serotypes. No FBS lot qualification, no BVDV testing burden.
Lentivirale Vektoren
HEK293T triple plasmid transfection for 3rd and 4th generation lentiviral packaging systems — CAR-T, gene correction, base editing vector production.
Recombinant Protein
Transient or stable recombinant protein expression in HEK293T — downstream purification simplified by absence of bovine serum proteins.
Häufig gestellte Fragen
How many passages does HEK293T adaptation to SimplaceX take?
Full adaptation typically takes 5–10 passages. Growth rate (doubling time) returns to FBS-equivalent levels over 5–20 further passages after initial adaptation. The suspension cell rescue protocol at every passage is the most important factor in reducing adaptation time.
What is the expected AAV titre in SimplaceX compared to FBS?
After full adaptation, AAV titres in SimplaceX are within 1.5× of optimised FBS (Low Endotoxin) in most HEK293T systems. Run a small-scale production test (one 15 cm dish) before committing to full-scale serum-free production.
Can I use SimplaceX directly without FBS reduction steps?
Not recommended. A stepwise FBS reduction (1% → 0.5% → 0%) over 3 passages before switching fully to SimplaceX gives significantly better adaptation outcomes than a direct switch. Cells adapt more stably and recover growth rate faster with the gradual approach.
What is the difference between SimplaceX and SimplaceCDX?
SimplaceX contains a defined protein supplement package — it is serum-free but not fully chemically defined. SimplaceCDX is fully chemically defined with no animal-derived or recombinant protein components — required for processes where CDM documentation is needed for GMP or regulatory filings. Adapt to SimplaceX first, then transition to SimplaceCDX if CDM is required.
Is SimplaceX available with a data sheet?
Yes — a full technical data sheet is included with every order and available on request prior to purchase.
Ähnliche Produkte & Anleitungen
Request SimplaceX — Sample or Quote
Available in 500 mL and 2,000 mL. Full data sheet included. Free test sample on request for adaptation evaluation.
English 
Deutsch